Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
BUSINESS
Takeda Shareholders Pitch Claw-Back Clause, Urge Execs to Return Pay If Loss Incurred on Big Investment
A group of shareholders of Takeda Pharmaceutical is making a proposal to add a “claw-back clause” to the company’s articles of incorporation, pressing its board members to return their compensations if excessive investments result in a significant profit correction or…
To read the full story
Related Article
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
- Claw-Back Clause Thwarted, but Majority of Takeda Shareholders Voted in Favor
July 4, 2019
- Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
June 28, 2019
- Takeda to Propose Adding Shire Integration as Performance Objective for Execs’ Stock Compensation
June 14, 2019
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
BUSINESS
- Daiichi, AZ Pull EU Dato-DXd Filing for Lung Cancer
December 25, 2024
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Increased Off-Year Pressure on LLPs Would Only Exacerbate Supply Crunch: Industry Officials
December 24, 2024
- Eisai/Fujirebio Tie Up in Biomarker Research for Neurodegenerative Diseases
December 24, 2024
- Orion Now MA Holder of Parkinson’s Meds Stalevo, Comtan in Japan
December 24, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…